Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Oslo, Norway, Oct 29, 2007 - (Hugin via ABN Newswire) - Oslo, Norway, 29 October 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, will announce its third quarter 2007 results on Friday, 9 November 2007. A presentation to investors, analysts and the press will take place in Oslo at 08:15 CET and an international conference call will take place at 14:30 CET (details below). Algeta's President and Chief Executive Officer, Dr. Thomas Ramdahl and Chief Financial Officer, Geir Christian Melen will host the presentation and the call.
The presentation will take place at 08:15 CET at:
Hotel Continental Stortingsgaten 24/26 0117 Oslo Norway.
Breakfast will be served from 07:45 CET.
Please contact Maj Liz Hatland at Algeta ASA on +47 23 00 79 90 if you would like to participate, or you may send an e-mail to maj.liz.hatland@algeta.com
To participate in the conference call, please dial the appropriate number below five minutes prior to the call:
The third quarter report and the presentation will be made available on www.algeta.com in the Investors section from 08:00 CET.
A replay version of the call will be available until 19 November 2007. To access the replay, please dial +47 67 89 40 91. Enter account no. 1428 followed by #, then press 1, conference no. 428 followed by #. Press 1 to play. A replay version of the conference call will also be available during the same period at www.algeta.com.
###
For further information, please contact
Dr Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) Geir Christian Melen, CFO +47 23 00 79 84 / +47 913 02 965 (mob) post@algeta.com
Dr Mark Swallow / David +44 (0) 207 638 9571 Dible mark.swallow@citigatedr.co.uk Citigate Dewe Rogerson
About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology.
Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.
Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.
Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.
